300 related articles for article (PubMed ID: 24788066)
1. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Rodrigues LB; Bravo R; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SO; Cronemberger S; Ferreira AJ; Faraco AA
PLoS One; 2014; 9(4):e95461. PubMed ID: 24788066
[TBL] [Abstract][Full Text] [Related]
2. Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.
Foureaux G; Franca JR; Nogueira JC; Fulgêncio Gde O; Ribeiro TG; Castilho RO; Yoshida MI; Fuscaldi LL; Fernandes SO; Cardoso VN; Cronemberger S; Faraco AA; Ferreira AJ
PLoS One; 2015; 10(7):e0133149. PubMed ID: 26204514
[TBL] [Abstract][Full Text] [Related]
3. Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation.
Franca JR; Foureaux G; Fuscaldi LL; Ribeiro TG; Castilho RO; Yoshida MI; Cardoso VN; Fernandes SOA; Cronemberger S; Nogueira JC; Ferreira AJ; Faraco AAG
Int J Pharm; 2019 Oct; 570():118662. PubMed ID: 31491481
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
5. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
[TBL] [Abstract][Full Text] [Related]
6. Topical Bimatoprost Insert for Primary Open-Angle Glaucoma and Ocular Hypertension Treatment - A Phase II Controlled Study.
Rubião F; Araújo ACF; Sancio JB; Nogueira BS; Franca JR; Nogueira JC; Ferreira AJ; Faraco AAG; Foureaux G; Cronemberger S
Curr Drug Deliv; 2021; 18(7):1022-1026. PubMed ID: 33388018
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Aburahma MH; Mahmoud AA
AAPS PharmSciTech; 2011 Dec; 12(4):1335-47. PubMed ID: 21979886
[TBL] [Abstract][Full Text] [Related]
8. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.
Curran MP; Orman JS
Drugs Aging; 2009; 26(2):169-84. PubMed ID: 19220073
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
11. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
12. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial.
Day DG; Walters TR; Schwartz GF; Mundorf TK; Liu C; Schiffman RM; Bejanian M
Br J Ophthalmol; 2013 Aug; 97(8):989-93. PubMed ID: 23743437
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%.
Frenkel RE; Noecker RJ; Craven ER
Curr Med Res Opin; 2008 Apr; 24(4):919-23. PubMed ID: 18267054
[TBL] [Abstract][Full Text] [Related]
14. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
Gelatt KN; Mackay EO
J Ocul Pharmacol Ther; 2002 Dec; 18(6):525-34. PubMed ID: 12537679
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
16. A case hypersensitive to bimatoprost and dexamethasone.
Li X; Liu G; Wang Y; Yu W; Xiang H; Liu X
J Ocul Pharmacol Ther; 2011 Oct; 27(5):519-23. PubMed ID: 21936632
[TBL] [Abstract][Full Text] [Related]
17. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
Brandt JD; Cantor LB; Katz LJ; Batoosingh AL; Chou C; Bossowska I;
J Glaucoma; 2008; 17(3):211-6. PubMed ID: 18414107
[TBL] [Abstract][Full Text] [Related]
18. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
19. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.
Katz LJ; Cohen JS; Batoosingh AL; Felix C; Shu V; Schiffman RM
Am J Ophthalmol; 2010 Apr; 149(4):661-671.e1. PubMed ID: 20346780
[TBL] [Abstract][Full Text] [Related]
20. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
Coleman AL; Lerner F; Bernstein P; Whitcup SM
Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
